With oral administration, Azilsartan is poorly absorbed; peak plasma concentrations occur 1 to 3 hours after a dose. The liver significantly metabolises the bioavailability, which is roughly 60 %. About 11 hours pass between half-lives. Azilsartan is an excellent option for the design and development of transdermal treatment systems due to its low therapeutic dose and significant liver biotransformation. An alternative dosage form for the current oral, parenteral medication delivery system was being developed as part of the current investigation. Azilsartan transdermal patches were made utilising a particular process and a combination of HPMC and EC polymers in various ratios. Several evaluation criteria, including thickness, folding endurance, weight uniformity, content uniformity, swelling index, percentage moisture content, moisture uptake, surface pH and in vitro release studies, PK study, and permeation study, were applied to all the patches that had been developed. Regarding integrity, flexibility, drug dispersion, and other quality control criteria, all patches displayed satisfactory features. In order to identify the drug release mechanism, the data were plotted. The medication release experiment of 24 hours was prolonged. The penetration was made better using DMSO, which untangled the lipid layer. Improved medication penetration is achieved by the formulation with a high concentration of HPMC (A1). The A2 and A6 helped maintain a steady pace of discharge. A sustain release polymeric transdermal patch was developed to deliver Azilsartan over the skin barrier gradually. This shows that Azilsartan transdermal application maintains the drug's claimed regulated release for a long time.